

UC Irvine

UC Irvine Previously Published Works

Title

Generation of Lytic Natural Killer 1.1+, Ly-49– Cells from Multipotential Murine Bone Marrow Progenitors in a Stroma-free Culture: Definition of Cytokine Requirements and Developmental Intermediates

Permalink

<https://escholarship.org/uc/item/211815bb>

Journal

Journal of Experimental Medicine, 186(9)

ISSN

0022-1007

Authors

Williams, Noelle Sevilir
Moore, Thomas A
Schatzle, John D
et al.

Publication Date

1997-11-03

DOI

10.1084/jem.186.9.1609

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Generation of Lytic Natural Killer 1.1⁺, Ly-49⁻ Cells from Multipotential Murine Bone Marrow Progenitors in a Stroma-free Culture: Definition of Cytokine Requirements and Developmental Intermediates

By Noelle Sevilir Williams,* Thomas A. Moore,† John D. Schatzle,* Igor J. Puzanov,* P.V. Sivakumar,* Albert Zlotnik,‡ Michael Bennett,* and Vinay Kumar*

From the *Laboratory of Molecular Pathology, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas 75235-9072; and †Immunology Department, DNAX Research Institute of Molecular and Cellular Biology, Palo Alto, California 94304-1104

Summary

We have developed a stroma-free culture system in which mouse marrow or thymus cells, known to be enriched for lymphoid progenitors, can be driven to generate natural killer (NK) cells. Culture of lineage marker (Lin)⁻, c-kit⁺, Sca2⁺, interleukin (IL)-2/15R β (CD122)⁻ marrow cells in IL-6, IL-7, stem cell factor (SCF), and flt3 ligand (flt3-L) for 5–6 d followed by IL-15 alone for an additional 4–5 d expanded the starting population 30–40-fold and gave rise to a virtually pure population of NK1.1⁺, CD3⁻ cells. Preculture in IL-6, IL-7, SCF, and flt3-L was necessary for inducing IL-15 responsiveness in the progenitors because the cells failed to significantly expand when cultured in IL-15 alone from the outset. Although culture of the sorted progenitors in IL-6, IL-7, SCF, and flt3-L for the entire 9–11-d culture period caused significant expansion, no lytic NK1.1⁺ cells were generated if IL-15 was not added, demonstrating a critical role for IL-15 in NK differentiation. Thus, two distinct populations of NK progenitors, IL-15 unresponsive and IL-15 responsive, have been defined. Similar results were obtained with Lin⁻, CD44⁺, CD25⁻, c-kit⁺ lymphoid progenitors obtained from adult thymus. The NK cells generated by this protocol lysed the NK-sensitive target YAC-1 and expressed markers of mature NK cells with the notable absence of Ly-49 major histocompatibility complex (MHC) receptors. However, despite the apparent lack of these inhibitory MHC receptors, the NK cells generated could distinguish MHC class I⁺ from class I⁻ syngeneic targets, suggesting the existence of novel class I receptors.

NK cells express two families of receptors, which in the murine system are known as NKR-P1 and Ly-49 (1). The NKR-P1 molecule is expressed on all NK cells of certain mouse strains and may play a role in triggering NK cytotoxicity. Conversely, the Ly-49 receptors, which recognize class I MHC molecules, are expressed on subsets of NK cells and inhibit NK-mediated lysis.

Despite increasing knowledge of NK cell function and target cell recognition, differentiation of NK cells from hematopoietic stem cells is poorly understood. NK cells are known to be bone marrow derived, and early work suggested an important role for the marrow microenvironment in generating mature lytic NK cells (2). To dissect the steps of NK differentiation, several *in vitro* systems have been established that allow the development of lytic NK cells from CD34⁺ human cells (3–6) or unseparated rodent bone marrow (reviewed in reference 7). However, in many of

these systems, the starting populations were heterogeneous, containing pluripotent stem cells and progenitors at different stages of development. In addition, the NK cells that developed were not fully characterized, especially with respect to the expression and function of class I MHC receptors.

Although IL-2 has frequently been used to support NK development, the failure to detect the IL-2 gene product within bone marrow stroma (8) and the presence of NK cells in IL-2^{-/-} mice (9) strongly suggests that cytokines other than IL-2 participate in NK cell differentiation *in vivo*. The newly described cytokine IL-15 has been shown to use both the common γ chain (γ c) and IL-2R β as components of its receptor (10), and it is produced by bone marrow stromal cell cultures (8). In addition, IL-15 supports development of NK cells from human CD34⁺ stem cells and murine fetal thymic cells (8, 11) and causes terminal differ-

entiation of immature, nonlytic NK1.1⁺ cells found in the spleen of marrow ablated mice (12).

In the present report, we describe an *in vitro* culture system yielding virtually pure populations of lytic NK1.1⁺ cells from lineage (Lin)⁻, c-kit⁺, and Sca2⁺ multipotent progenitors in the absence of stroma. The data show that a mixture of early acting cytokines and IL-15 play sequential and important roles in the differentiation of NK cells from these marrow progenitors.

Materials and Methods

Animals. 7–12-wk C57BL/6 mice were bred at The University of Texas Southwestern Medical Center (Dallas, TX) and used for bone marrow progenitor experiments. 4–5-wk (C57BL/6 × BALB/C)F1 mice (Jackson Labs., Bar Harbor, ME) were used for thymic progenitor experiments.

mAbs. Except as noted below, all mAbs and their isotype controls were obtained from PharMingen (San Diego, CA). Anti-gp49B1 FITC (B23.1) was the gift of Dr. H. Katz (Harvard University, Boston, MA), anti-Ly-49G2 (4D11) and anti-Ly-49D (12A8) were provided by Dr. J. Ortaldo (National Cancer Institute, Frederick, MD), anti-Ly-49A (JR9-318) was the gift of Dr. J. Roland (Institut Pasteur, Paris, France), and anti-Sca2 hybridoma supernatant was provided by Dr. G. Spangrude (University of Utah, Salt Lake City, UT). Goat anti-rat γ Texas red (Southern Biotechnology Assoc., Birmingham, AL) or streptavidin-Red670 (GIBCO BRL, Gaithersburg, MD) was used to detect some primary antibodies.

Cell Preparation, Isolation, and Analysis of Precursor Cells. Cell suspensions of bone marrow and thymocytes were prepared as previously described (13, 14). Staining was performed on ice in PBS/5 mM EDTA at 3×10^6 cells/ml. For three-color sorting of bone marrow progenitors, cells were incubated with anti-Fc γ RIII/II (2.4G2) and then with a mixture of lineage-specific biotinylated antibodies: anti-B220 (RA3-6B2), anti-CD2 (RM2-5), anti-Gr1 (RB6-8C5), anti-CD11b (M1/70), and anti-NK1.1 (PK136) followed by streptavidin magnetic beads (Miltenyi Biotec Inc., Auburn, CA). After washing, the cells were passed over a CS column (Miltenyi Biotec Inc.) to remove Lin⁺ cells. The Lin-depleted population was then stained with streptavidin-Red670, c-kit (2B8) PE, and Sca2 (thymic shared antigen [TSA]1) FITC. Lin-Red670⁻, c-kit PE⁺, Sca2 FITC⁺ cells of lymphoid and blast size were then sorted on a FACStar Plus[®] flow cytometer (Becton Dickinson, San Jose, CA) using Lysis II software. The identification and isolation of CD4^{lo} (CD44⁺, CD25⁻, c-kit⁺, Lin⁻) has been previously described (14).

For four-color analysis of marrow progenitors, cells were stained sequentially with anti-Sca2 hybridoma supernatant, goat anti-rat γ Texas red, 10% normal rat serum, the cocktail of biotinylated Lin-specific mAbs described above, and finally a mixture of streptavidin-Red670, c-kit FITC, or PE and either CD44 (IM7) PE, IL-2/15R β (TM- β 1) PE, HSA (M1/69) FITC, or CD4 (H129.19) FITC. Analysis of cultured cells was performed by sequential staining with 2.4G2, a biotinylated mAb, and finally streptavidin-Red670 plus an FITC- and/or PE-conjugated mAb.

Culture Conditions. Sorted Lin⁻, c-kit⁺, Sca2⁺ marrow cells were cultured in 96-well U-bottomed plates (Falcon, San Jose, CA) at 8,000–10,000 cells/well in 0.2 ml of complete RPMI-1640 (10% FBS, 100 U/ml streptomycin, 1 mM sodium pyruvate, 2 mM glutamine, 1 \times nonessential amino acids, 50 μ g/ml gentamicin, 5 $\times 10^{-5}$ M 2-mercaptoethanol, and 1 μ g/ml Indomethacin) plus 20

ng/ml murine IL-15 (a gift from Dr. Tony Trout, Immunex R&D Corp., Seattle, WA) or a mixture of 20 ng/ml murine IL-6 (PharMingen), 0.5 ng/ml murine IL-7 (PeproTech, Rocky Hill, NJ), 50 ng/ml rat stem cell factor (SCF; a gift from Amgen, Thousand Oaks, CA), and 100 U/ml murine flt3 ligand (flt3-L; DNAX, Palo Alto, CA). The cells were refed with the same media on day 3, and then on day 5 or 6 the cultures were harvested, washed, counted, and replated at 10,000–15,000/well in complete RPMI containing IL-15 alone or the mixture of cytokines described above. After an additional 3 d, the cultures were refed with the same media, and on day 11 or 12 of total culture time, the cells were harvested for analysis. Sorted Lin⁻, CD44⁺, CD25⁻, c-kit⁺ thymic progenitors were cultured as previously described (15), and the two-step culture protocol described above for marrow progenitors was followed.

Target Cells and Cytotoxicity Assays. Tumor targets used were YAC-1 (H-2^a); RMA (H-2^b); a transport associated with antigen processing (Tap)-2 mutant derivative of RMA, RMA-S (H-2^b); and a Tap-2 transfectant of RMA-S, Q11 (H-2^b; reference 16), which was a kind gift of Dr. J. Monaco (University of Cincinnati, Cincinnati, OH). All cell lines were maintained in supplemented RPMI-1640 (17); Q11 additionally received 1 mg/ml G418. Target cells were used in a 4-h ⁵¹Cr cytotoxicity assay, and percent specific lysis was expressed as the mean \pm SEM of triplicate wells and calculated as described earlier (17).

RNA Extraction, PCR Amplification, and Southern Analysis. Total RNA was prepared from whole cells using a modification of the Chomczynski and Sacchi method. Reverse transcription was performed using the Superscript II system (GIBCO BRL) and PCR using the GIBCO BRL PCR kit with standard PCR buffer (1.5 mM MgCl₂) for 35 cycles (94°C for 30 s, 55°C for 30 s, 72°C for 1 min). Primers were designed from the published IL-15R α sequence (18). Under these conditions, the forward primer (CTCCAGGCTGACACCATC) and reverse primer (CATGGTTTCCACCTCAACACGGCA) yield a 282-bp product. PCR products were transferred to Hybond N plus (Amersham Life Science Corp., Arlington Heights, IL) and probed with an end-labeled internal IL-15R α oligo (GAGAACGTCGTTGTTACTG) at 55°C. IL-2-cultured NK cells served as a positive control for IL-15R α message, and RNA integrity was confirmed by amplification of glyceraldehyde-3-phosphate-dehydrogenase (GAPDH).

Results and Discussion

Isolation and Characterization of a Lin⁻, c-kit⁺, Sca2⁺ Bone Marrow Population. We previously identified a multipotential bone marrow population characterized as Ly6 (Sca1)⁺, Lin⁻, c-kit (CD117)⁺, CD43^{hi}, Fall-3^{hi}, Sca2 (TSA1)⁻, AA4^{lo}, and Rh123^{hi} with both lymphoid and myeloid repopulating abilities *in vivo* (13). Upon adoptive transfer, this population also gives rise to NK cells (13). To define a population capable of giving rise to NK cells *in vitro*, a marker more restricted to the lymphoid lineage was sought. TSA-1, also known as Sca2 (19), was previously found to delineate a population of Lin⁻, Thy-1^{lo}, HSA (CD24)⁺ bone marrow cells enriched for lymphoid (T and B cell) repopulating ability, but essentially devoid of pluripotent stem cells (20). Because NK cells may share a common progenitor with T and B cells (21) and may indeed derive from an NK/T precursor (11, 22), we hypothesized that a marrow population expressing Sca2 may also contain NK progenitors. Thus,

Table 1. Expansion and Generation of NK Cells from Lin^- , $c-kit^+$, $Sca2^+$ Bone Marrow Progenitors Cultured in IL-6, IL-7, SCF, and $flt3-L \pm IL-15$

Primary culture		Secondary culture		Total	
Cytokines	Yield*	Cytokines	Yield*	Yield [†]	NK1.1 ⁺
					%
IL-15	0.3	IL-15	1.0	0.3	ND
6/7/SCF/ <i>flt3-L</i>	9.4	6/7/SCF/ <i>flt3-L</i>	8.7	81.8	2
6/7/SCF/ <i>flt3-L</i>	9.4	IL-15	3.8	35.7	85

Sorted progenitors were cultured in the two-part culture system as described in Materials and Methods. NK1.1 expression was assessed using PE-labeled anti-NK1.1 mAb (PK136) from PharMingen. The data are representative of six experiments.

*Yield represents the fold increase in total cell number.

[†]Total yield is the product of the yield in the primary and secondary cultures.

a Lin^- (CD2, B220, Gr1, CD11b, NK1.1)⁻, $c-kit^+$, $Sca2^+$ population, representing ~1% of whole bone marrow, was isolated. Four-color analysis revealed that these cells were CD44^{hi}, HSA^{int}, and CD4⁻ (data not shown). The phenotype of this population is similar to a CD4^{lo}, CD8⁻, CD3⁻, CD44⁺, $Sca2^+$, $c-kit^+$, CD25⁻ lymphoid progenitor from thymus (23) and to a related CD4^{-/lo}, Lin^- , Thy1^{lo}, HSA^{int}, CD44^{hi}, and $Sca2^+$ population isolated from bone marrow with predominant lymphoid and limited myeloid repopulating abilities (20).

Culture of Lin^- , $c-kit^+$, $Sca2^+$ Multipotent Progenitors. To determine the ability of this "lymphoid-enriched" progenitor population to give rise to NK cells, sorted Lin^- , $c-kit^+$, $Sca2^+$ cells were cultured with IL-15 for 9–11 d. However, these cells failed to expand significantly in IL-15 alone (Table 1). Cell recovery on average ($n = 6$) was only 1.8-fold




Figure 1. Lytic activity of Lin^- , $c-kit^+$, $Sca2^+$ cells cultured with a cocktail of early acting cytokines \pm IL-15. Sorted cells were cultured in the indicated cytokines as described in Materials and Methods. Cytotoxic activity was assessed on YAC-1 tumor cells. The data are representative of six experiments.




Figure 2. Expression of IL-15R α messenger RNA and IL-2/15R β on Lin^- , $c-kit^+$, $Sca2^+$ progenitors and an IL-15-responsive population derived by culture of the progenitors in IL-6, IL-7, SCF, and *flt3-L*. (A) IL-15R α message levels were determined with RNA isolated from sorted Lin^- , $c-kit^+$, $Sca2^+$ progenitors in two experiments (lanes 1 and 2) and from a population of splenic NK cells (45% NK1.1⁺ by flow cytometry) derived by culture of spleen cells in 500 U/ml of recombinant human IL-2 for 4 d (lane 3). (B) IL-2/15R β expression was examined by flow cytometry on gated Lin^- , $c-kit^+$, $Sca2^+$ cells using PE-labeled anti-IL-2/15R β mAb TM- β 1. The data are representative of three experiments. (C) Sorted Lin^- , $c-kit^+$, $Sca2^+$ cells, cultured for 5 d in IL-6, IL-7, SCF, and *flt3-L*, were stained for IL-2/15R β expression using FITC-labeled TM- β 1. Shaded curves represent staining with TM- β 1, whereas open curves represent staining with isotype control mAbs. The data are representative of two experiments.

over the input numbers of cells, but these cells did lyse the NK-sensitive tumor YAC-1 (Fig. 1). It is possible that a small number of the progenitors are truly capable of responding to IL-15 alone. We do not favor this hypothesis because cell surface expression of IL-2/15R β was not detected on the sorted population (Fig. 2 B), and the β chain is usually required for signal transduction (24). Alternatively, this growth may represent contamination by rare mature NK cells.

Although the sorted marrow progenitor cells failed to expand significantly when cultured in IL-15 only, when cultured for 5–6 d in IL-6, IL-7, SCF, and *flt3-L* and then placed in IL-15 alone for an additional 4–5 d, significant expansion occurred (Table 1), and the majority of cells generated were NK1.1⁺ and lytic (Table 1 and Fig. 1). If the cultures were maintained in the original cocktail instead of switching to IL-15, significant expansion again occurred, but no lytic activity and few, if any, NK1.1⁺ cells were detectable. Together these data indicate that culture of sorted Lin^- , $c-kit^+$, $Sca2^+$ progenitors in the early acting cytokines causes expansion and primes at least some cells within this population to respond to IL-15 alone. The identity of other cells generated in the presence of the cytokine cocktail and absence of IL-15 is still being explored, but a small fraction (~13%) are CD19⁺, sIgM⁻, indicative of immature B cells, whereas a larger fraction (~63%) express high levels of CD11b. Thus, it appears that this population may be multipotential. The data also point to a critical role for IL-15 in NK differentiation because culture of the multipotential progenitors, "primed" by early cytokines in IL-15 only, generated a population of predominantly NK1.1⁺ cells.

Table 2. Expansion and Generation of NK Cells from Lin^- , $CD44^+$, $CD25^-$, $c-kit^+$ Thymic Progenitors Cultured in IL-3 or $flt3-L$ and IL-6, IL-7, and SCF \pm IL-15

Primary culture (6–7 d)		Secondary culture (6–7 d)		Total Yield	% NK1.1 ⁺
Cytokines	Yield	Cytokines	Yield		
IL-15	0				
3/6/7-SCF	10.4	IL-15	5.8	60.3	93
6/7/SCF/ $flt3-L$	ND	6/7/SCF/ $flt3-L$	–	40*	1.8
6/7/15/SCF/ $flt3-L$	ND	6/7/15/SCF/ $flt3-L$	–	381*	86

Sorted Lin^- , $CD44^+$, $CD25^-$, $c-kit^+$ thymic progenitors were cultured for the indicated number of days and analyzed as described in Table 1.

*In these experiments, only the total yield was determined after the secondary culture.

Similar experiments were performed using immature thymic progenitors (Lin^- , $CD44^+$, $CD25^-$, $c-kit^+$, $CD4^{lo}$) previously shown to generate T, B, and NK cells (14, 23). When these cells were cultured with IL-15 alone, all cells died within 72 h (Table 2). However, like the marrow progenitor population, when this thymic population was cultured in a cocktail of early acting cytokines and then switched to culture with IL-15 only, significant expansion was observed and a virtually pure population of NK1.1⁺ cells was generated. In initial experiments, the primary culture was performed in IL-3, IL-6, IL-7, and SCF because this mixture is known to maintain and expand lymphoid progenitors (14). Because IL-3 is a T cell-derived cytokine that should not be required for NK differentiation, we hypothesized that the NK progenitors would develop in the absence of IL-3. Indeed, culture in IL-6, IL-7, IL-15, SCF, and $flt3-L$ for 13 d generated large numbers of an 86% pure population of NK cells, whereas culture in the absence of IL-15 failed to give rise to NK1.1⁺ cells but did result in significant expansion (Table 2).

Expression of IL-15R α and IL-2/15R β by Sorted Population and Developmental Intermediates. The ability of IL-6, IL-7, SCF, and $flt3-L$ to induce IL-15 responsiveness in sorted Lin^- , $c-kit^+$, $Sca2^+$ cells suggested that this mixture of cytokines may be inducing expression of functional IL-15 receptors. Sorted Lin^- , $c-kit^+$, $Sca2^+$ bone marrow cells were thus examined for IL-15R α expression by PCR and IL-2/15R β expression by FACS[®] analysis. Interestingly, the freshly sorted cells did express transcripts of IL-15R α (Fig. 2 A), but they failed to show cell surface expression of IL-2/15R β (Fig. 2 B). Furthermore, preliminary evidence has indicated surface expression of the γ_c by a small proportion of these cells (data not shown). These data suggest that the failure of sorted Lin^- , $c-kit^+$, $Sca2^+$ cells to expand significantly in IL-15 alone is most likely due to the absence of IL-2/15R β expression. We, therefore, anticipated that culture of Lin^- , $c-kit^+$, $Sca2^+$ cells in IL-6, IL-7, SCF, and $flt3-L$ would induce IL-2/15R β expression. Indeed, after primary culture, ~13% of the progenitors expressed IL-2/15R β (Fig. 2 C), but not NK1.1 (data not shown). Upon further culture in IL-15, the vast majority of the NK1.1⁺

cells generated also expressed IL-2/15R β (data not shown). These data thus suggest that IL-2/15R β expression may precede that of NK1.1, and its acquisition may be a critical event in NK cell differentiation. This idea is supported by the absence of NK cells in IL-2/15R $\beta^{-/-}$ mice (25) and isolation of an IL-2/15R β^+ , NK1.1⁻ population from SCID bone marrow that can give rise to lytic NK1.1⁺ cells upon culture in IL-15 (our unpublished data).

Cell Surface Profile of In Vitro Generated NK Cells. The NK cells generated by culture of marrow progenitor cells were




Figure 3. Ly-49 profile of NK cells generated from culture of Lin^- , $c-kit^+$, $Sca2^+$ progenitors. Expression of NK1.1 was analyzed by setting a “live” gate based on forward and side scatter of the cells, whereas expression of the remainder of the markers was analyzed on NK1.1⁺, live cells. Shaded curves represent staining with the NK1.1 or Ly49 mAbs, whereas open curves represent staining with isotype control mAbs. The data are representative of four separate experiments.




Figure 4. Lysis of syngeneic Tap^{+/+} and Tap^{-/-} tumor cells by in vitro generated NK cells. Target cells were class I⁺ RMA (Tap^{+/+}) and Q11 (Tap^{+/+}) and class I⁰ RMA-S (Tap^{-/-}). The data are representative of three separate experiments.

phenotypically quite similar to mature IL-2-activated splenic NK cells (12, 26, 27). They were CD3⁻, CD11b⁺, FcγRIII/II⁺, IL-2/15Rβ⁺, c-kit⁻, and 2B4⁺ (data not shown) and lysed the NK-sensitive target YAC-1 (Fig. 1). Interestingly, they also expressed gp49B1, an inhibitory receptor of the Ig superfamily shared by mast cells (28). However, they failed to express the Ly-49 family of MHC receptors (Fig. 3). In four experiments, expression of Ly-49A, C/I, and D was undetectable or <3% over isotype controls, whereas mature C57BL/6 splenic NK1.1⁺ cells are 20% Ly-49A⁺, 50% Ly-49C/I⁺, and 50% Ly-49D⁺. Expression of Ly-49G2 was slightly more variable ranging from 2–8% over isotype controls, whereas nearly 50% of splenic NK cells express this receptor. We have been unable to ascertain whether the in vitro-derived NK cells truly express low levels of Ly-49G2 or whether this antibody simply shows nonspecific binding. In any case, these data suggest that NK cells acquire expression of NK1.1 before expression of Ly-

49 receptors. The factors required for induction of Ly-49 molecules are unknown, but it is clear that IL-15 alone is not sufficient.

Cytotoxic Activity of In Vitro-generated NK Cells Against Class I⁺ and Class I⁻ Tumor cells. It has been demonstrated that interaction of Ly-49 receptors with their appropriate MHC class I ligands sends an inhibitory signal to NK cells and prevents NK-mediated lysis of the class I⁺ target (1). However, despite the failure to express significant levels of Ly-49 MHC receptors, these in vitro-derived NK cells differentiated class I⁺ from class I⁻ syngeneic tumor cells. They lysed class I⁰ Tap-deficient RMA-S cells but failed to lyse RMA, the class I⁺ parent of RMA-S (Fig. 4). That this difference in lysis was due to the absence of class I on the surface of RMA-S is supported by the observation that the culture-derived NK cells failed to lyse Q11, a class I⁺ Tap-2 transfectant of RMA-S (16).

In summary, we have developed a stroma-free culture system capable of generating lytic NK1.1⁺ cells from a defined multipotential progenitor population contained in the bone marrow. This system has allowed identification of a putative (NK1.1⁻) developmental intermediate in NK differentiation, characterized by expression of IL-2/15Rβ and the ability to respond to IL-15. One or all of a mixture of cytokines including IL-6, IL-7, SCF, and flt3-L was shown to be critical in reaching this developmental stage. This study also provided additional evidence for the critical role that IL-15 plays in NK differentiation, because no NK1.1⁺ cells were detected in its absence. IL-15 was not, however, capable of inducing expression of the Ly-49 family of MHC molecules, suggesting that some stimulus necessary to induce Ly-49 expression was missing from this culture system. Finally, these data suggested that development of lytic activity and expression of NK1.1 can precede expression of Ly-49 molecules; however, despite the absence of these receptors, the in vitro-derived NK cells could distinguish class I⁺ from class I⁻ syngeneic tumor cells, suggesting the existence of novel class I receptors.

This work was supported by National Institutes of Health grants AI25401, AI38938, CA36922, and CA70134. DNAX Research Institute of Molecular and Cellular Biology is supported by Schering-Plough Corporation.

The authors would like to thank Angie Mobley and Bonnie Darnell for expert assistance in all aspects of flow cytometry and cell sorting.

Address correspondence to Dr. Noelle S. Williams, Laboratory of Molecular Pathology, Department of Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9072. Phone: 214-648-4081; FAX: 214-648-4033; E-mail: williams.n@pathology.swmed.edu

Received for publication 30 June 1997 and in revised form 5 September 1997.

References

1. Brown, M.G., A.A. Scalzo, K. Matsumoto, and W.M. Yokoyama. 1997. The natural killer gene complex: a genetic basis for understanding natural killer cell function and innate immunity. *Immunol. Rev.* 155:53–65.
2. Kumar, V., J. Ben-Ezra, M. Bennett, and G. Sonnenfeld. 1979. Natural killer cells in mice treated with ⁸⁹Strontium: normal target-binding cell numbers but inability to kill even after interferon administration. *J. Immunol.* 123:1832–1838.

3. Miller, J.S., C. Verfaillie, and P. McGlave. 1992. The generation of human natural killer cells from CD34⁺/DR⁻ primitive progenitors in long-term bone marrow culture. *Blood*. 80:2182–2187.
4. Silva, M.R.G., R. Hoffman, E.F. Srour, and J.L. Ascensao. 1994. Generation of human natural killer cells from immature progenitors does not require marrow stromal cells. *Blood*. 84:841–846.
5. Shibuya, A., K. Nagayoshi, K. Nakamura, and H. Nakauchi. 1995. Lymphokine requirement for the generation of natural killer cells from CD34⁺ hematopoietic progenitor cells. *Blood*. 85:3538–3546.
6. Bennett, I.M., O. Zatsepina, L. Zamai, L. Azzoni, T. Mikheeva, and B. Perussia. 1996. Definition of a natural killer NKR-P1A⁺/CD56⁻/CD16⁻ functionally immature human NK cell subset that differentiates *in vitro* in the presence of interleukin 12. *J. Exp. Med.* 184:1845–1856.
7. Moore, T.A., M. Bennett, and V. Kumar. 1996. Murine natural killer cell differentiation: past, present, and future. *Immunol. Res.* 15:151–162.
8. Mrozek, E., P. Anderson, and M.A. Caligiuri. 1996. Role of Interleukin-15 in the development of human CD56⁺ natural killer cells from CD34⁺ hematopoietic progenitor cells. *Blood*. 87:2632–2640.
9. Kündig, T.M., H. Schorle, M.F. Bachmann, H. Hengertner, R.M. Zinkernagel, and I. Horak. 1993. Immune responses in interleukin-2-deficient mice. *Science (Wash. DC)*. 262:1059–1061.
10. Giri, J.G., M. Ahdieh, J. Eisenman, K. Shanebeck, K. Grabstein, S. Kumaki, A. Namen, L.S. Park, D. Cosman, and D. Anderson. 1994. Utilization of the β and γ chains of the IL-2 receptor by the novel cytokine IL-15. *EMBO (Eur. Mol. Biol. Organ.) J.* 13:2822–2830.
11. Leclercq, G., V. Debacker, M. De Smedt, and J. Plum. 1996. Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/natural killer progenitor cells. *J. Exp. Med.* 184:325–336.
12. Puzanov, I.J., M. Bennett, and V. Kumar. 1996. IL-15 can substitute for the marrow microenvironment in the differentiation of natural killer cells. *J. Immunol.* 157:4282–4285.
13. Moore, T., M. Bennett, and V. Kumar. 1995. Transplantable NK cell progenitors in murine bone marrow. *J. Immunol.* 154:1653–1663.
14. Moore, T.A., and A. Zlotnik. 1995. T-cell lineage commitment and cytokine responses of thymic progenitors. *Blood*. 86:1850–1860.
15. Moore, T.A., and A. Zlotnik. 1997. Differential effects of Flk-2/Flt-3 ligand and stem cell factor on murine thymic progenitor cells. *J. Immunol.* 158:4187–4192.
16. Attaya, M., S. Jameson, C.K. Martinez, E. Hermel, C. Al-drach, J. Forman, K.F. Lindahl, M.J. Bevan, and J.J. Monaco. 1992. Ham-2 corrects the class I antigen-processing defect in RMA-S cells. *Nature (Lond.)*. 355:647–649.
17. Yu, Y.Y.L., T. George, J.R. Dorfman, J. Roland, V. Kumar, and M. Bennett. 1996. The role of Ly49A and 5E6 (Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. *Immunity*. 4:67–76.
18. Giri, J.G., S. Kumaki, M. Ahdieh, D.J. Friend, A. Loomis, K. Shanebeck, R. DuBose, D. Cosman, L.S. Park, and D.M. Anderson. 1995. Identification and cloning of a novel IL-15 binding protein that is structurally related to the α chain of the IL-2 receptor. *EMBO (Eur. Mol. Biol. Organ.) J.* 14:3654–3663.
19. Godfrey, D.I., M. Masicantoni, C.L. Tucek, M.A. Malin, R.L. Boyd, and P. Hugo. 1992. Thymic shared antigen-1. A novel thymocyte marker discriminating immature from mature thymocyte subsets. *J. Immunol.* 148:2006–2011.
20. Antica, M., L. Wu, K. Shortman, and R. Scollay. 1994. Thymic stem cells in mouse bone marrow. *Blood*. 84:111–117.
21. Georgopoulos, K., M. Bigby, J.H. Wang, A. Molnar, P. Wu, S. Winandy, and A. Sharpe. 1994. The Ikaros gene is required for the development of all lymphoid lineages. *Cell*. 79:143–156.
22. Sánchez, M.J., M.O. Muench, M.G. Roncarolo, L.L. Lanier, and J.H. Phillips. 1994. Identification of a common T/natural killer cell progenitor in human fetal thymus. *J. Exp. Med.* 180:569–576.
23. Wu, L., M. Antica, G.R. Johnson, R. Scollay, and K. Shortman. 1991. Developmental potential of the earliest precursor cells from the adult mouse thymus. *J. Exp. Med.* 174:1617–1627.
24. Goldsmith, M.A., and W.C. Greene. 1994. Interleukin-2 and the interleukin-2 receptor. In *The Cytokine Handbook*. A.W. Thomson, editor. Academic Press Limited, San Diego. 57–80.
25. Suzuki, H., G.S. Duncan, H. Takimoto, and T.W. Mak. 1997. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor β chain. *J. Exp. Med.* 185:499–505.
26. Trinchieri, G. 1989. Biology of natural killer cells. *Adv. Immunol.* 47:187–376.
27. Garni-Wagner, B.A., A. Purohit, P.A. Mathew, M. Bennett, and V. Kumar. 1993. A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells. *J. Immunol.* 151:60–70.
28. Wang, L.L., I.K. Mehta, P.A. LeBlanc, and W.M. Yokoyama. 1997. Mouse natural killer cells express gp49B1, a structural homologue of human killer inhibitory receptors. *J. Immunol.* 158:13–17.